Covance, Parexel Will Pursue Smaller Acquisitions Following Merger Failure
Executive Summary
Covance has approximately $750 mil. in acquisition resources readily available to continue its consolidation and diversification efforts in the CRO and pharmaceutical support areas after the breakup of the Parexel purchase.
You may also be interested in...
FDA Pledges 10% Reduction In NDA Review Time As Part Of “Strategic Plan”
FDA plans to deliver a two-month reduction in review times for standard new molecular entity NDA filings as one "benchmark" for the agency's "strategic plan.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011